Research
Hormonal
Patients with active psychiatric disorders, particularly depression, may exhibit lower response rates to semaglutide and are at risk of weight gain during treatment.
If you have active depression or other psychiatric conditions, monitor your weight closely when starting semaglutide, as some patients may not lose weight or may even gain weight.
ModerateQualifiesLOW confidence
Patients with psychiatric disorders were overrepresented in the non-responders group... three individuals, all females with active major depressive disorder, increased their body weight during the period of semaglutide treatment.
Why this rating
Small sample size (n=9 with psychiatric disorders) limits statistical power.
Source
A Real-World Study of the Effectiveness and Safety of Semaglutide for Weight Loss
Ploutarchos Tzoulis et al. · Cureus · 2024
DOI 10.7759/cureus.59558
cohort · n=40Cited 13×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →